Lifesciences@Work : We help scientists build their business


DCPrime is dedicated to creating more effective immunotherapy products for the treatment of cancer. The company has developed a unique platform technology which allows the generation of off-the-shelf dendritic cell (DC)-based vaccines. The platform combines the power of DC-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products. With this powerful platform, DCPrime has the opportunity to become the next generation dendritic cell product.